Where Innovation Grows: Phytome’s Evolution into a Global Force in Botanical Science - translating Research & Development Into Transformational Novel Medicines
Phytome’s evolution continued its upward trajectory in 2025, building upon the strong foundation established in previous years. The Company stands at an incredibly exciting point in its journey, as we translate successful research and development into drug development through pre-clinical testing programmes. What began as ambitious facility construction has evolved into a leading technology platform where botanical medicine development becomes reality.
We have developed a team, gained the licences and built a unique technology platform to deliver as a biotechnology company focussed on unlocking the chemical potential of plants. Our recent achievements demonstrate the successful transition from research infrastructure to operational excellence.
- UK-Saudi Innovation Event
- Precision Genetics
- Pharmaceutical excellence
Commercial Momentum and International Expansion
The UK-Saudi innovation bridge represents our most significant development since securing original Home Office licensing in 2022. Through strategic partnerships with Saudi Arabia’s Research, Development and Innovation Authority, we’re establishing a foothold in the Kingdom that provides unprecedented access to expertise and global markets to expedite our scaling up. This expansion positions us uniquely in the international botanical medicine landscape.
Our Contract Research Organisation partnerships are moving beyond discussions and into formal agreements that are expected to be formalised imminently, generating revenue streams that validate our platform’s commercial viability.
Science With Momentum
Proprietary seed breeding continues to refine the optimal process for high-quality seed and plant vitality with clone-equivalent chemical profiles – a cornerstone of our ability to deliver standardised, pharmaceutical-grade botanical medicines. The cultivation of crops for Epilepsy and IBD projects continues through conformity and extraction trials to refine processes and target key active molecules in the medicine. The team has immediately utilised our new formulation lab, batch testing target formulations and conditions that can scale to industrial preparation under GMP.
The facility expansion also enables enhanced drying and extraction capabilities, with our CO2 extraction protocols successfully yielding promising initial extracts. This innovation, combined with advances in other downstream processing steps, positions Phytome to meet the rigorous standards required for prescription medicines.
LOOKING AHEAD: TRANSFORMATION AND GLOBAL IMPACT
Over the next 12 months Phytome aims to achieve significant value inflection points through obtaining IND (Investigational New Drug) approval of our two breakthrough medicines and assembling a world-class medical advisory board, whilst in parallel strengthening and expanding our collaboration and commercial interests in The Kingdom of Saudi Arabia.
Phytome’s journey exemplifies how innovation rooted in Cornwall can achieve global impact. We’ve created something truly unique – a technology platform that transforms nature’s pharmacy into standardised, scalable pharmaceutical solutions. The plant medicine epicentre we envisioned is now a multinational reality.
- Saudi Arabia & Cornish Flag flying together